ANDA 213927, held by Adaptis. Venlafaxine Hydrochloride.
As of Nov 18, 2026, ANDA 213927 (Venlafaxine Hydrochloride), held by Adaptis, was first approved by FDA on Jan 21, 2021, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 21, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Venlafaxine HydrochlorideEQ 75MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Jan 3, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 13, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 21, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters